Novartis Message Board - Msg: 13300602

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 122.63

+0.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (273)	3/28/2000 8:41:00 PM
From: Jack Hartmann	Read Replies (1) of 296

Swiss Business Briefs: Novartis Eye Therapy Advances Dow Jones Newswires 3/28/2000 ZURICH -- Novartis AG (Z.NOV) said Phase III study of its Visudyne therapy produced benefits for patients with two vision conditions, age-related macular degeneration and choroidal neovascularization. Visudyne therapy is being jointly developed by Ciba Vision, a unit of Novartis, and QLT PhotoTherapeutics Inc (QLT). No further ifo, but looks good. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next